Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis

Authors Pressler T

Published 5 December 2008 Volume 2008:2(4) Pages 611—617

DOI https://doi.org/10.2147/BTT.S3052

Review by Single-blind

Peer reviewer comments 1

Tacjana Pressler

CF Centre, Dept. of Pediatrics, Rigshospitalet, University of Copenhagen Denmark

Abstract: The most important problem in cystic fibrosis (CF) lung disease is chronic airway inflammation and infection, which starts early in life. To prevent severe lung damage, it is important to mobilize as much sputum as possible from the lung on a daily basis. RhDNase is an enzyme that breaks down DNA strands in airway secretions, hydrolyzes the DNA present in sputum/mucus of CF patients, reducing viscosity in the lungs and promoting secretion clearance. Several well performed trials have proven its efficacy in young CF patients with mild disease as well as in older patients with more advanced lung disease. Daily inhalation of this agent slows down lung function decline and decreases the frequency of respiratory exacerbations. The drug is well tolerated by most patients independent of the severity of lung disease.

Keywords: cystic fibrosis, lung disease, recombinant human deoxyribonuclease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]